Effect of vitamin D supplementation on cardiovascular risk in type 2 diabetes.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Whether vitamin D affects lipid profile and cardiovascular disease (CVD) risk is controversial.

Who Took Part

According to the abstract, 127 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Changes in lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides [TG] and TG/HDL ratio), C-reactive protein and CVD risk (calculated according the American College of Cardiology/American Heart Association [ACC/AHA] guidelines) were assessed at week 24 and 48.

What Was Measured

PubMed files the paper under topics including C-Reactive Protein, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dietary Supplements, Lipids and Vitamin D.

Author keywords: Cardiovascular risk, Clinical trial and Lipid profile.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 127 patients.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.